TaiGen Biotechnology
0
0
0
About
Overview
Steering Committee
Career
Management Team
Milestones
Board of Directors
About Us
TaiGen is a discovery-based and market-focused pharmaceutical company engaging in the development of novel therapeutics for infectious diseases and other indications with high degree of unmet medical needs.
R&D Center
Pipeline
R&D Progress
Antibiotic
Taigexyn®
Influenza Antiviral
Pixavir (TG-1000)
HIF-PHD Inhibitor
ISM-4808
Dipeptidyl Peptidase 1 (DPP1) Inhibitor
TG-4318
Stem Cell Mobilizer
Burixafor
HCV Antiviral
Furaprevir
Research
R&D Center
TaiGen’s dedicated team of professional scientists perform cutting edge research in drug discovery to advance programs efficiently. Our pipeline of anti-infective & anti-inflammatory programs are the fruits of both internal research as well as in-licensed programs.
News
News
Investors
Investors
Financial Information
Material Information
Material Information
Shareholders' Information
Shareholders' Information
Corporate Governance
Investor FAQs
Investors
Communicating with investors, cultivating long-term investor relations and highlighting corporate’s value.
Business & Partnership
ESG
Contact Us
Home
繁中
Shareholders' Information
Shareholders' Information
Shareholders' Information
Investor Conference
Stock Quote
Dividend Information
Contact Us
Stock Quote
check historical information please refer to
Taipei Exchange
，Stock Code4157。
Stock Code
Recent Price
Change（%）
Trade Vol. （1,000 shares）
4157
8.48
0.02 (0.24%)
33
Taipei Exchange
Open
High
Low
Taipei Exchange
8.55
8.71
8.46
Home
Investors
Shareholders' Information
Stock Quote